Galectin-3 in vitro diagnostic assay (BG Medicine Inc.) for the management of patients with chronic heart failure
Record ID 32014000390
English
Authors' recommendations:
There are 5 to 6 million people in the United States with heart failure (HF); the risk of its development is 1 in 5 for both men and women. Serum biomarkers can be a convenient way to assess HF prognosis and response, including galectin-3, a protein derived from cardiac tissue. Currently, B-type natriuretic peptide (BNP) and amino-terminal proB-type natriuretic peptide NTproBNP are used to determine prognostic categories for patients with HF. These 2 blood tests are recommended by the American College of Cardiology Foundation and the American Heart Association for patients with dyspnea in whom the contribution of HF is unknown. However, BNP and NTproBNP are influenced by age, renal function, and anemia. An emerging marker of ventricular remodeling and fibrosis is the serum protein galectin-3.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=15848
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Enzyme-Linked Immunosorbent Assay
- Galectin 3
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2013 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.